Cargando…

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy

BACKGROUND/OBJECTIVE: Observational clinical data from cladribine-treated patients with relapsing forms of multiple sclerosis (MS) were recorded in the Australian MS registry powered by the MSBase registry platform (5-year follow-up) and analysed to complement information from the pivotal cladribine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lizak, Nathaniel, Hodgkinson, Suzanne, Butler, Ernest, Lechner-Scott, Jeannette, Slee, Mark, McCombe, Pamela Ann, Shaw, Cameron, Skibina, Olga, Vucic, Steve, Shuey, Neil, Barnett, Michael H, Parratt, John, Butzkueven, Helmut, Jack, Dominic, Fabris, Jessica, Kalincik, Tomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897790/ https://www.ncbi.nlm.nih.gov/pubmed/32530363 http://dx.doi.org/10.1177/1352458520921087

Ejemplares similares

The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform
por: Jokubaitis, Vilija G., et al.
Publicado: (2013)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
por: Maltby, Vicki E, et al.
Publicado: (2021)

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
por: Spelman, Tim, et al.
Publicado: (2022)

The MSBase pregnancy, neonatal outcomes, and women’s health registry
por: Jokubaitis, Vilija G., et al.
Publicado: (2021)

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry
por: Rojas, Juan Ignacio, et al.
Publicado: (2015)

Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study
por: Barnett, Michael, et al.
Publicado: (2021)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy
por: Wiendl, Heinz, et al.
Publicado: (2022)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data
por: Hardy, Todd A, et al.
Publicado: (2022)

The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis
por: Lycett, Mitchell J, et al.
Publicado: (2023)

Impairment of Smooth Pursuit as a Marker of Early Multiple Sclerosis
por: Lizak, Nathaniel, et al.
Publicado: (2016)

Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort
por: Talman, Paul, et al.
Publicado: (2016)

Application of population pharmacokinetics to cladribine
por: Lindemalm, Synnöve, et al.
Publicado: (2005)

Cladribine: Lymphopenia: case report
Publicado: (2021)

Cladribine modifies functional properties of microglia
por: Jørgensen, L. Ø., et al.
Publicado: (2020)

Cladribine: Lymphopenia: 2 case reports
Publicado: (2020)

Immunomodulatory Effects Associated with Cladribine Treatment
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
por: Brochet, Bruno, et al.
Publicado: (2023)

Erdheim Chester Disease treated successfully with cladribine
por: Azadeh, Natalya, et al.
Publicado: (2016)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2018)

Expert-Agreed Practical Recommendations on the Use of Cladribine
por: Meca-Lallana, Virginia, et al.
Publicado: (2022)

Magnetic Multi-Enzymatic System for Cladribine Manufacturing
por: Cruz, Guillermo, et al.
Publicado: (2022)

The Short and Long-Term Effects of Pregnancy on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
por: McCombe, Pamela A
Publicado: (2018)

Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium
por: Broadley, James, et al.
Publicado: (2021)

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients
por: Dwyer, Christopher M., et al.
Publicado: (2021)

The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis
por: Merlo, Daniel, et al.
Publicado: (2019)

Correction to: Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2019)

Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine
por: Hermann, Robert, et al.
Publicado: (2021)

10th International Conference on Electronic Properties of Two-dimensional Systems
por: McCombe, B D, et al.
Publicado: (1994)

Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis
por: Campagna, Maria Pia, et al.
Publicado: (2023)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies
por: Laurencet, F M, et al.
Publicado: (1999)

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine
por: Schreiner, Teri L., et al.
Publicado: (2012)

Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis
por: Grobost, Vincent, et al.
Publicado: (2014)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis
por: Helbig, Grzegorz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_70civ20ctk5vnngsjdecet4n6a